Call for Abstracts and Abstract Submission Guidelines
The EAACI Scientific Programme Committee and the Local Organising Committee welcome the submission of original contributions for oral and poster presentation at the Congress.
DEADLINE: 15 JANUARY 2018 at 24:00 CET
Instructions to authors
Carefully read the guidelines below before submitting your abstract. Acknowledgement of the receipt of your submission will be sent to the corresponding author’s e-mail address immediately upon submission. If you do not receive the confirmation e-mail, please do not submit the abstract again. Instead please contact the Abstract team at email@example.com for advice. Invited speakers are not required to submit abstracts to the lectures they are invited to.
• Abstracts can only be submitted electronically through the congress website.
• You are allowed to be the presenting author of more than one abstract.
• You are allowed to be a co-author of more than one abstract.
• Submissions of similar abstracts from the same group are discouraged.
• Abstracts that have been or will be presented at a different scientific meeting during a 12 months period prior to EAACI 2018 can be submitted.
• Please note, a confirmation of consent must be provided in cases where patients, both living or deceased, are visibly identifiable.Should consent not be given, any pictures must be made anonymous by placing sufficient coverage over any identifiable elements; eyes, facial features, characterising marks etc.
When entering the abstract submission system for the first time, you will be asked to create a profile. Through your account you will be able to access your personal page to submit one or several abstracts. You can edit your abstracts until the submission deadline, 15 January 2018.
Abstract language and length
Abstracts and presentations must be written in English. The maximum length allowed for an abstract is 2500 characters (approximately 350 words) including blank spaces. The abstract title, the author(s) or names of institutions are not included in the count of 2500 characters.
Abstract structure and content
In order to make the abstract as informative as possible, please include a brief statement of the purpose of the study and/or the underlying hypotheses, the method used, the results observed, and the conclusions based upon the results. It is inadequate to state “The results will be discussed” or “The data will be presented”. You may subtitle the paragraphs in the following order: Background, Method, Results, and Conclusion.
50 characters per row will be deducted from the word count.
No pictures are allowed.
The abstract title and body text should only include pharmacopoeia names printed in lower case. Trade names are not allowed. Non-proprietary (generic) names of drugs, written in lower case, are required the first time a drug is mentioned in the text. References, credits or the authors’ academic degrees or grant support are not to be included in the abstract. Standard abbreviations may be employed in the text. Place special or unusual abbreviations in parentheses after the full wording at the first time it appears in the body of the text. Company names are not allowed in the title but can be named in the authors’ affiliation.
Consent for publication of individual patient data - applies to abstracts with identifiable patient information
For the publication of an abstract that contains identifiable information about patients, it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent for the publication of these must be obtained from the patient (or their parent or legal guardian).
It is the author’s responsibility to obtain written informed consent for publication of clinical details and/or clinical images from the patient/parent/guardian/relative of the patient. A respective statement needs to be included in the abstract text.
Duplication of publications
Abstracts containing data that has been presented or will be presented at a different scientific meeting during a 12 months period prior to EAACI 2018 can be submitted.
Declaration of conflict of interest
EAACI is committed to ensuring the integrity of its scientific, educational, and research programmes. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.
Abstract submission deadline 2018-01-15